Last reviewed 2026-05-23 · How we verify

Rabeprazole, Amoxicillin

Rabeprazole, Amoxicillin is a Proton pump inhibitor + Beta-lactam antibiotic combination Small molecule drug developed by Mackay Memorial Hospital. It is currently FDA-approved for Helicobacter pylori eradication in peptic ulcer disease, H. pylori-associated gastritis. Also known as: Pariet, Supercillin.

Rabeprazole and amoxicillin work together to eradicate Helicobacter pylori by suppressing gastric acid and inhibiting bacterial cell wall synthesis.

Rabeprazole is a small molecule medication used to treat Helicobacter Pylori Infection, Helicobacter Gastritis, and Helicobacter-Associated Pyloric Ulcer, often in combination with other medications such as amoxicillin. Amoxicillin is an antibiotic that is commonly used in combination with rabeprazole to treat these conditions.

At a glance

Mechanism of action

Rabeprazole is a proton pump inhibitor that reduces gastric acid secretion, creating an environment where amoxicillin (a beta-lactam antibiotic) can effectively penetrate and kill H. pylori bacteria by disrupting their cell wall synthesis. This combination therapy is a standard triple or dual therapy regimen for H. pylori eradication, typically used with a third agent such as clarithromycin or metronidazole.

Approved indications

• Helicobacter pylori eradication in peptic ulcer disease
• H. pylori-associated gastritis

Common side effects

• Diarrhea
• Nausea
• Abdominal pain
• Headache
• Rash (amoxicillin-related)
• Taste disturbance

Key clinical trials

• The Impact of Helicobacter Pylori Eradication on the Vaginal Microecology Change
• Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy and Bismuth Quadruple Therapy (NA)
• Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy, Vonoprazan-amoxicillin Dual Therapy and Proton Pump Inhibitor-based Standard Triple Therapy for Hp Eradication (NA)
• Helicobacter Pylori Infection and Gastric Disease in Bhutan: First Community-Wide, Population-Based Study (NA)
• Efficacies of Susceptibility-guided vs Empiric Therapy for Rescue Treatment of Helicobacter Pylori Infection (PHASE4)
• Efficacy and Safety of Rifasutenizol (TNP 2198), Rabeprazole and Amoxicillin in Participants With H. Pylori Infection (PHASE3)
• Efficacy and Safety of Keverprazan-amoxicillin Dual Therapy for Helicobacter Pylori First-line Treatment (PHASE4)
• Efficacies of HDDT With or Without Bismuth vs Amoxicillin-metronidazole BQT for First-line H Pylori Eradication (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Rabeprazole, Amoxicillin CI brief — competitive landscape report
• Rabeprazole, Amoxicillin updates RSS · CI watch RSS
• Mackay Memorial Hospital portfolio CI

Frequently asked questions about Rabeprazole, Amoxicillin

Related

• Drug class: All Proton pump inhibitor + Beta-lactam antibiotic combination drugs
• Target: All drugs targeting H+/K+-ATPase (rabeprazole); Bacterial penicillin-binding proteins (amoxicillin)
• Manufacturer: Mackay Memorial Hospital — full pipeline
• Therapeutic area: All drugs in Gastroenterology
• Indication: Drugs for Helicobacter pylori eradication in peptic ulcer disease
• Indication: Drugs for H. pylori-associated gastritis
• Also known as: Pariet, Supercillin

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing